Cargando…
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control study
AIM: To determine the influence of high-efficacy disease modifying therapy (DMT) on the development of IgG SARS-CoV-2 antibody response in COVID-19 convalescent people with multiple sclerosis (pwMS). METHODS: Seventy-four pwMS taking high-efficacy DMTs (specifically natalizumab, fingolimod, alemtuzu...
Autores principales: | Habek, Mario, Jakob Brecl, Gregor, Bašić Kes, Vanja, Rogić, Dunja, Barun, Barbara, Gabelić, Tereza, Emeršič, Andreja, Horvat Ledinek, Alenka, Grbić, Nevena, Lapić, Ivana, Šegulja, Dragana, Đurić, Koraljka, Adamec, Ivan, Krbot Skorić, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366037/ https://www.ncbi.nlm.nih.gov/pubmed/34418815 http://dx.doi.org/10.1016/j.jneuroim.2021.577696 |
Ejemplares similares
-
Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod
por: Krbot Skorić, Magdalena, et al.
Publicado: (2022) -
Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies
por: Habek, Mario, et al.
Publicado: (2022) -
Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab
por: Habek, Mario, et al.
Publicado: (2022) -
Evolution of tongue somatosensory evoked potentials in people with multiple sclerosis
por: Krbot Skorić, Magdalena, et al.
Publicado: (2020) -
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness
por: Barun, Barbara, et al.
Publicado: (2021)